Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes

Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G, for the BENEDICT Study Group 

For assessment of the independent renoprotective effect of blood pressure (BP) control and angiotensin-converting enzyme inhibitor therapy, the relationships of baseline BP, BP reduction, and follow-up BP with the incidence of persistent microalbuminuria were evaluated in 1204 hypertensive patients who had type 2 diabetes and normoalbuminuria and were included in the BErgamo Nephrologic Diabetic Complications Trial (BENEDICT) study. (more) 

 


Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G, for the BENEDICT Study Group. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol. 2006;17:3472-3481. 

Last Modified: 2/4/2013